Coya Therapeutics, Inc. (NASDAQ:COYA – Free Report) – Equities researchers at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Coya Therapeutics in a research report issued on Wednesday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.39). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.52) EPS.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%.The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million.
View Our Latest Stock Analysis on Coya Therapeutics
Coya Therapeutics Stock Performance
COYA stock opened at $5.26 on Friday. The firm has a market cap of $123.40 million, a P/E ratio of -4.57 and a beta of 0.55. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The stock has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $5.04.
Hedge Funds Weigh In On Coya Therapeutics
A number of institutional investors have recently made changes to their positions in COYA. Renaissance Technologies LLC boosted its stake in shares of Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after buying an additional 37,064 shares during the last quarter. Cetera Investment Advisers raised its holdings in Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after acquiring an additional 8,000 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Coya Therapeutics by 205.2% in the first quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock valued at $377,000 after acquiring an additional 64,490 shares in the last quarter. XTX Topco Ltd bought a new position in Coya Therapeutics during the 4th quarter valued at $192,000. Finally, Occudo Quantitative Strategies LP acquired a new position in Coya Therapeutics during the 4th quarter worth $66,000. 39.75% of the stock is owned by institutional investors and hedge funds.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.
See Also
- Five stocks we like better than Coya Therapeutics
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
